|Bid||7.29 x 800|
|Ask||7.30 x 3000|
|Day's Range||7.29 - 7.33|
|52 Week Range||2.02 - 7.84|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 30, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.67|
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MENLO PARK, Calif., Feb. 26, 2019 -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and.
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -61.54% and -7.37%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Menlo Park, California-based company said it had a loss of 21 cents per share. The maker of genetic analysis technology posted revenue of $19.5 million in the period, which did not meet Street forecasts. ...
MENLO PARK, Calif., Feb. 11, 2019 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its fourth quarter and year ended December 31,.
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, Dec. 31, 2018 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Red Hat, Inc., LSC.
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / JuanMonteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...
NEW YORK, Dec. 10, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Pacific Biosciences of California, Inc. (NASDAQ:.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (“Pacific Biosciences” or the “Company”) (NASDAQ GS: PACB) related to the Company’s entry into an agreement to be acquired by Illumina, Inc. (“Illumina”) (NASDAQ GS: ILMN) in a transaction announced on November 1, 2018 (the “Proposed Transaction”). On November 1, 2018, the Board caused Pacific Biosciences to enter into an agreement and plan of merger (the “Merger Agreement”) with Illumina. Pursuant to the terms of the agreement, shareholders of Pacific Biosciences will receive $8.00 in cash for each share of Pacific Biosciences common stock.
NEW YORK , Dec. 6, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.
Pacific Biosciences of California stock rose from $2.64 at the close of market on December 29, 2017, to $7.47 at the close of market on November 21, 2018, representing a ~183% year-to-date rise. PACB hit its 52-week high of $7.84 on November 8. On November 1, Pacific Biosciences entered into an agreement with Illumina (ILMN) wherein Illumina agreed to acquire it.
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.
Pacific Biosciences of California Inc., (PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that an international team of scientists have published the highest quality genome assembly to date of the Aedes aegypti mosquito genome using its Single Molecule, Real-Time (SMRT®) technology. “The high-quality genome assembly and annotation described here will enable major advances in mosquito biology and has already allowed us to carry out a number of experiments that were previously impossible,” the authors write.
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Pacific Biosciences of California, Inc. (PACB), a company that offers sequencing systems to help scientists resolve genetically complex problems. PacBio® sequencing systems, including consumables and software, provide a simple and fast end-to-end workflow for SMRT sequencing. On November 1, 2018, the Company announced they had signed an agreement for Illumina to acquire Pacific Biosciences in an all-cash transaction.
Here's what derailed the drug, and why Illumina is paying $1.2 billion to acquire Pacific Biosciences.